Sanofi (SNY) News Today $51.35 +0.74 (+1.46%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$51.02 -0.33 (-0.64%) As of 08/22/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNY Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Rep. Lisa C. McClain Buys Sanofi (NASDAQ:SNY) StockAugust 23 at 8:06 AM | marketbeat.comLegacy Financial Advisors Inc. Takes Position in Sanofi $SNYAugust 23 at 5:49 AM | marketbeat.comHighTower Advisors LLC Sells 8,497 Shares of Sanofi $SNYAugust 23 at 4:25 AM | marketbeat.comSanofi $SNY Shares Sold by Wellington Management Group LLPAugust 22 at 5:05 AM | marketbeat.comSanofi $SNY Stock Holdings Lowered by Aberdeen Group plcAugust 22 at 4:18 AM | marketbeat.comSanofi $SNY Shares Purchased by Brooklyn Investment GroupAugust 21 at 4:59 AM | marketbeat.comNovavax downgraded to Underperform at BofA on ‘murky outlook’August 20, 2025 | msn.comRaymond James Financial Inc. Acquires 425,597 Shares of Sanofi $SNYAugust 20, 2025 | marketbeat.comSanofi $SNY Shares Sold by American Century Companies Inc.August 20, 2025 | marketbeat.comSanofi $SNY Shares Purchased by Kovitz Investment Group Partners LLCAugust 20, 2025 | marketbeat.comSummit Securities Group LLC Acquires Shares of 41,680 Sanofi (NASDAQ:SNY)August 19, 2025 | marketbeat.com10,000 Shares in Sanofi (NASDAQ:SNY) Purchased by Corient IA LLCAugust 19, 2025 | marketbeat.comSanofi (NASDAQ:SNY) Receives Average Recommendation of "Buy" from AnalystsAugust 19, 2025 | marketbeat.comSanofi (NASDAQ:SNY) Shares Bought by Ethic Inc.August 18, 2025 | marketbeat.comVestmark Advisory Solutions Inc. Grows Holdings in Sanofi (NASDAQ:SNY)August 18, 2025 | marketbeat.comRussell Investments Group Ltd. Grows Stake in Sanofi (NASDAQ:SNY)August 18, 2025 | marketbeat.comSanofi (NASDAQ:SNY) Receives Average Rating of "Buy" from AnalystsAugust 18, 2025 | americanbankingnews.comRep. Lisa C. McClain Sells Off Shares of Sanofi (NASDAQ:SNY)August 17, 2025 | marketbeat.comBrandywine Global Investment Management LLC Lowers Stake in Sanofi (NASDAQ:SNY)August 17, 2025 | marketbeat.comNeuberger Berman Group LLC Increases Stock Position in Sanofi (NASDAQ:SNY)August 17, 2025 | marketbeat.comSanofi’s Promising Study on Amlitelimab for Celiac Disease: A Potential Market Game-ChangerAugust 15, 2025 | msn.comSanofi’s Latest Clinical Trial: A New Hope for Advanced Solid Tumors?August 15, 2025 | msn.comSanofi’s Dupilumab Study: A Closer Look at Long-term Treatment for Prurigo NodularisAugust 15, 2025 | msn.comSanofi’s Phase 3 Study on Frexalimab: A Potential Game-Changer for Multiple Sclerosis TreatmentAugust 15, 2025 | msn.comSanofi’s Phase 3 Study on Belumosudil for CLAD: A Potential Game-ChangerAugust 15, 2025 | msn.comSanofi’s New Study on Rilzabrutinib: A Potential Breakthrough for ITP TreatmentAugust 15, 2025 | msn.comSanofi’s New Phase 2a Study: A Potential Game-Changer in Kidney Disease TreatmentAugust 15, 2025 | msn.comSanofi’s New Osteoarthritis Drug Study: A Potential Game Changer?August 15, 2025 | tipranks.comSanofi’s Pediatric Atopic Dermatitis Study: Key Insights for InvestorsAugust 15, 2025 | tipranks.comBoston Partners Sells 1,307,291 Shares of Sanofi (NASDAQ:SNY)August 15, 2025 | marketbeat.comVirtu Financial LLC Takes Position in Sanofi (NASDAQ:SNY)August 15, 2025 | marketbeat.comSanofi (NASDAQ:SNY) Stake Boosted by Regal Partners LtdAugust 14, 2025 | marketbeat.comSanofi (NASDAQ:SNY) Position Lowered by Mondrian Investment Partners LTDAugust 14, 2025 | marketbeat.comPress Release: Sanofi's rilzabrutinib earns orphan designation in the EU for IgG4-related diseaseAugust 14, 2025 | globenewswire.comSanofi’s Phase 3 Study on Belumosudil: A Potential Game-Changer for Lung Transplant PatientsAugust 13, 2025 | tipranks.comSanofi’s Dupilumab Study: A Potential Game-Changer for Prurigo Nodularis TreatmentAugust 13, 2025 | tipranks.comNuveen LLC Purchases Shares of 3,206,466 Sanofi (NASDAQ:SNY)August 13, 2025 | marketbeat.comSanofi’s Teplizumab Study: A New Hope for Type 1 Diabetes TreatmentAugust 12, 2025 | theglobeandmail.comSanofi stops supply of high cholesterol drug to China due to limited availabilityAugust 12, 2025 | reuters.comCitigroup Inc. Acquires 180,127 Shares of Sanofi (NASDAQ:SNY)August 12, 2025 | marketbeat.comSanofi (NASDAQ:SNY) Shares Sold by Invesco Ltd.August 11, 2025 | marketbeat.comManhattan West Asset Management LLC Increases Stake in Sanofi (NASDAQ:SNY)August 10, 2025 | marketbeat.comZions Bancorporation National Association UT Invests $11.50 Million in Sanofi (NASDAQ:SNY)August 9, 2025 | marketbeat.comSanofi (NASDAQ:SNY) Upgraded by JPMorgan Chase & Co. to Overweight RatingAugust 9, 2025 | marketbeat.comSanofi (NASDAQ:SNY) Shares Sold by Primecap Management Co. CAAugust 8, 2025 | marketbeat.comSanofi’s SAR444881 Study Terminated: Implications for InvestorsAugust 7, 2025 | msn.comRegeneron and Sanofi’s Phase 3 Itepekimab Study: A Potential Game Changer for CRSwNP TreatmentAugust 7, 2025 | msn.comSanofi’s New Asthma Treatment Study: Potential Market Game-ChangerAugust 7, 2025 | msn.comSanofi’s Asthma Study: A Long-term Look at Lunsekimig’s PotentialAugust 7, 2025 | msn.comSanofi Finalizes Acquisition of Vigil Neuroscience to Boost Neurology PipelineAugust 7, 2025 | tipranks.com Get Sanofi News Delivered to You Automatically Sign up to receive the latest news and ratings for SNY and its competitors with MarketBeat's FREE daily newsletter. Email Address SNY Media Mentions By Week SNY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SNY News Sentiment▼1.420.69▲Average Medical News Sentiment SNY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SNY Articles This Week▼1725▲SNY Articles Average Week Get Sanofi News Delivered to You Automatically Sign up to receive the latest news and ratings for SNY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NVS News AZN News NVO News GSK News TAK News ARGX News ONC News BNTX News INSM News TEVA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SNY) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sanofi Please log in to your account or sign up in order to add this asset to your watchlist. Share Sanofi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access